Journal for ImmunoTherapy of Cancer · 2021 · 27 citations · 41 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyNeuroimmunologyCancer ImmunotherapyComplement-targeted TherapyTherapeutic Monoclonal AntibodiesTumor-associated AntigensAntibodiesAntitumor Immune ActivationComplement Activation PathwaysComplement System ActivationNeuroblastoma BiologyNeutrophil-mediated DamageNeutrophil-mediated InflammationNeutrophil-mediated Injury
BACKGROUND: The addition of monoclonal antibody therapy against GD2 to the treatment of high-risk neuroblastoma led to improved responses in patients. Nevertheless, administration of GD2 antibodies against neuroblastoma is associated with therapy-limiting neuropathic pain. This severe pain is evoked at least partially through complement activation on GD2-expressing sensory neurons. METHODS: To reduce pain while maintaining antitumor activity, we have reformatted the approved GD2 antibody ch14.18 into the IgA1 isotype. This novel reformatted IgA is unable to activate the complement system but efficiently activates leukocytes through the FcαRI (CD89). RESULTS: IgA GD2 did not activate the complement system in vitro nor induced pain in mice. Importantly, neutrophil-mediated killing of neuroblastoma cells is enhanced with IgA in comparison to IgG, resulting in efficient tumoricidal capacity of the antibody in vitro and in vivo. CONCLUSIONS: Our results indicate that employing IgA GD2 as a novel isotype has two major benefits: it halts antibody-induced excruciating pain and improves neutrophil-mediated lysis of neuroblastoma. Thus, we postulate that patients with high-risk neuroblastoma would strongly benefit from IgA GD2 therapy.
41
Quantitative assessment of tactile allodynia in the rat paw
Sandra R. Chaplan, Flemming W. Bach, J W Pogrel et al. · Journal of Neuroscience Methods · 1994 · 7.9K citations
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · New England Journal of Medicine · 2010 · 1.8K citations · Full text
Medicine, Immunology, Oncology +14
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 401 citations
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Shahab Asgharzadeh, Jill Salo, Lingyun Ji et al. · Journal of Clinical Oncology · 2012 · 285 citations · Full text
Medicine, Immunology, Oncology +17